ReviewPatient preference and adherence2016
Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®).
Review in Patient preference and adherence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Inhaler device feature preferences among patients with obstructive lung diseases: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis.Chronic respiratory diseasePooled it
- Inspiratory capacity and inhalation techniques evaluated and training by digital therapy comprehensive management platform in COPD patients.BMC pulmonary medicine · 2026Article
- A guide for a patient-centric approach to asthma management: results of a European Delphi consensus programme.NPJ primary care respiratory medicine · 2025Review
- Challenges and Opportunities for the Management of COPD: A Narrative Review of Patient and Health Care Professional Perspectives.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Inhaled non-viral delivery systems for RNA therapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Downstream Effects of Market Changes on Inhalers: Impacts on Individuals With Chronic Lung Disease.Respiratory care · 2024Review
- Climate-conscious inhaler prescribing for family physicians.Canadian family physician Medecin de famille canadien · 2024Review
- An approach to reduce inhaler errors using Donabedian's triad.Frontiers in medical technology · 2024Article
- Impact of Pharmacist-Led Intervention on Adherence to Inhalers, Inhalation Technique, and Disease Control Among Asthma/COPD Patients in a Resource Limited Center: An Interventional Study.Patient preference and adherence · 2024Article
- Pressurized metered-dose inhalers and their impact on climate change.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Shared Decision-Making Facilitates Inhaler Choice in Patients with Newly-Diagnosed Chronic Obstructive Pulmonary Disease: A Multicenter Prospective Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMATApplied health economics and health policy · 2020Article
- ELLIPTA Versus DISKUS plus HandiHaler in COPD: A Randomized, Open-Label, Crossover Study in a Clinical Trial Setting.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020Article
- A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMATAdvances in therapy · 2019Article
- Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design.ERJ open research · 2019Article
- Tiotropium/Olodaterol: A Review in COPD.Drugs · 2019Review
- Anticholinergics in asthma: are we utilizing asthma therapies effectively?Therapeutics and clinical risk management · 2019Article
- Choosing the right inhaler for your asthma or COPD patient.Therapeutics and clinical risk management · 2019Review
- Assessment of physical functioning and handling of tiotropium/olodaterol RespimatInternational journal of chronic obstructive pulmonary disease · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor inhaler technique hampers the efficacy of drug therapy in asthma and chronic obstructive pulmonary disease. Not only does this affect individual patient care, but it also impacts on the wider health care economics associated with these conditions. Treatment guidelines recommend a systematic approach to drug class selection; however, standardization of inhaler selection is currently difficult owing to the complexity of the interaction between the inhaler device and the patient. Specifically, individual patient preference can influence how successful a treatment is overall. This article reviews inhaler devices from the patient perspective, with a particular focus on the dry powder inhaler HandiHaler(®) and Respimat(®) Soft Mist™ Inhaler. It discusses factors that influence device preference and treatment compliance and reviews tools that can aid health care professionals to better match inhaler devices to individual patients' needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.